Morgan Stanley’s CARGO Therapeutics CRGX Stock Holding History

Morgan Stanley’s Portfolio CRGX Stock Details CRGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-445,022	Closed	-$1.83M	–	8201
2025 Q2	$1.83M	Buy	445,022 +162,200	+57%	+$695K	﹤0.01%	4756
2025 Q1	$1.15M	Buy	282,822 +197,387	+231%	+$1.32M	﹤0.01%	4941
2024 Q4	$1.23M	Sell	85,435 -8,452	-9%	-$153K	﹤0.01%	4985
2024 Q3	$1.73M	Buy	93,887 +70,734	+306%	+$1.27M	﹤0.01%	4737
2024 Q2	$380K	Sell	23,153 -15,122	-40%	-$288K	﹤0.01%	5413
2024 Q1	$854K	Sell	38,275 -98,719	-72%	-$2.35M	﹤0.01%	5054
2023 Q4	$3.17M	Buy	+136,994	New	+$2.32M	﹤0.01%	4671

Other funds holding CRGX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's CRGX Position: Q3 2025 in Review

Morgan Stanley sold out of CARGO Therapeutics (CRGX) in Q3 2025, closing a stake of 445,022 shares — an estimated $1.83M sold.

Morgan Stanley first reported a position in CRGX in Q4 2023 and held it in 7 quarters. The position peaked at $3.17M in Q4 2023. 1 fund tracked by Wall St. Rank holds CRGX as of Q3 2025.

Morgan Stanley reported no remaining CARGO Therapeutics position as of Q3 2025 after selling out during the quarter.
Morgan Stanley sold 445,022 CARGO Therapeutics shares in Q3 2025, an estimated $1.83M.
Morgan Stanley first reported a position in CARGO Therapeutics in Q4 2023 and held it in 7 quarters.
Morgan Stanley's CARGO Therapeutics position peaked at $3.17M in Q4 2023.
1 fund tracked by Wall St. Rank held CARGO Therapeutics as of Q3 2025.

Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.